Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States

Figure 1. Distribution of blood pressure (A), lipids (B), and fasting plasma glucose (C), by treatment status, in China and the United States (US), from 2011 to 2012. HDL indicates high‐density lipoprotein; and LDL, low‐density lipoprotein.

Figure 2. Prevalence of dyslipidemia (we defined dyslipidemia as total cholesterol [TC] ≥240 mg/dL, low‐density lipoprotein [LDL‐C] cholesterol ≥160 mg/dL, high‐density lipoprotein [HDL‐C] cholesterol <40 mg/dL, triglycerides [TG] ≥200 mg/dL, or taking lipid‐modifying medications, according to the 2007 Chinese guidelines on the prevention and treatment of dyslipidemia) and prevalence of each component, in China and the United States (US), from 2011 to 2012.

Figure 3. Mean fasting plasma glucose and prevalence of diabetes mellitus, in China and the United States (US), from 2011 to 2012.

Figure 4. Mean body mass index (BMI) and prevalence of BMI categories, in China and the United States (US), from 2011 to 2012.

Figure 5. Distribution of high‐sensitivity C‐reactive protein (high‐sensitivity C‐reactive protein data are from NHANES [US National Health and Nutrition Examination Survey] 2009–2010, because they were unavailable in NHANES 2011–2012), in China and the United States (US), from 2011 to 2012.

Figure 6. Clustering of cardiometabolic risk factors (hypertension, dyslipidemia, diabetes mellitus, overweight, and obesity) in China and the United States (US), from 2011 to 2012.